Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Stress Effectiveness of Psoriasis Drug Lumicef in Promotion: President
August 2, 2016
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
- Janssen Files HIV Combo Pill in Japan
August 1, 2016
- Otsuka Ups January-June Profit Forecasts
August 1, 2016
- Taiho Seeks Two Add’l Indications for Zosyn
August 1, 2016
- Chugai Hemophilia A Treatment Yields Positive Data in Japan PI/II
July 29, 2016
- Astellas, Cytokinetics Expand Collaboration into ALS
July 29, 2016
- Damage Suit Filed over HPV Vaccines; MSD Says Claims Scientifically Unfounded
July 28, 2016
- Teijin Files Somatuline for Neuroendocrine Tumor in Japan
July 28, 2016
- Ono Seeks Japan OK for Opdivo’s Head and Neck Cancer Indication
July 28, 2016
- Sumitomo Dainippon Trio to Research Method for Pre-RPE Cell Transplant Immune Reaction Testing
July 27, 2016
- Hisamitsu’s Allergic Rhinitis Drug Delivers Positive PIII Data
July 27, 2016
- Astellas Kicks Off Japan PIII for Renal Anemia Drug Roxadustat
July 27, 2016
- Hisamitsu’s US Unit Noven Transfers Rights to 2 Products to Sebela
July 27, 2016
- Luvox/Depromel Filed for Pediatric Obsessive-Compulsive Disorder in Japan: AbbVie, Meiji
July 26, 2016
- Asahi Kasei Pharma Seeks Nod for Longer Treatment Period for Teribone
July 25, 2016
- Fujifilm “Considering” Acquisition of Takeda’s Chemical Unit: Official
July 22, 2016
- PD-L1 Antibody Atezolizumab in Japan PIII for 7 Indications: Chugai
July 22, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Kyowa Kirin Ups January-June Earnings Guidance
July 22, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…